Leerink Partnrs Has Bearish Outlook for BBIO FY2027 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for BridgeBio Pharma in a note issued to investors on Sunday, November 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of $1.30 per share for the year, down from their prior forecast of $1.31. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a report on Monday, September 16th. HC Wainwright increased their price target on BridgeBio Pharma from $43.00 to $49.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer assumed coverage on BridgeBio Pharma in a report on Thursday, October 3rd. They set a “market perform” rating on the stock. Leerink Partners cut their price target on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, Bank of America increased their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.43.

BridgeBio Pharma Trading Down 2.8 %

Shares of NASDAQ BBIO opened at $26.44 on Tuesday. The stock has a 50-day moving average price of $24.97 and a two-hundred day moving average price of $26.21. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $44.32. The company has a market cap of $5.00 billion, a price-to-earnings ratio of -10.97 and a beta of 1.09.

Institutional Trading of BridgeBio Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its stake in BridgeBio Pharma by 22.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock valued at $24,859,000 after purchasing an additional 145,594 shares during the last quarter. First Turn Management LLC acquired a new position in shares of BridgeBio Pharma in the 3rd quarter valued at about $10,178,000. Jennison Associates LLC acquired a new position in BridgeBio Pharma in the 3rd quarter worth about $767,000. Comerica Bank raised its holdings in BridgeBio Pharma by 3,013.5% in the 1st quarter. Comerica Bank now owns 38,514 shares of the company’s stock worth $1,191,000 after purchasing an additional 37,277 shares during the period. Finally, Frazier Life Sciences Management L.P. raised its holdings in BridgeBio Pharma by 6.4% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,632,604 shares of the company’s stock worth $92,014,000 after purchasing an additional 217,000 shares during the period. Institutional investors own 99.85% of the company’s stock.

Insider Activity at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the sale, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $2,101,116.78. This represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the transaction, the insider now owns 25,260,971 shares in the company, valued at $650,470,003.25. The trade was a 18.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,831,545 shares of company stock valued at $150,056,923. Insiders own 24.66% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.